{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:53:56Z","timestamp":1782183236098,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.abb.2023.109541","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:58:54Z","timestamp":1675684734000},"page":"109541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inflammatory process and oxidative\/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy"],"prefix":"10.1016","volume":"737","author":[{"given":"Camila","family":"Aguilar Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica Lamberty","family":"Faverzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciele","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Regla","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2023.109541_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","article-title":"Growth charts for patients affected with Morquio A disease","volume":"146A","author":"Monta\u00f1o","year":"2008","journal-title":"Am. J. Med. Genet."},{"issue":"2","key":"10.1016\/j.abb.2023.109541_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1590\/S0034-72992003000200019","article-title":"S\u00edndrome de Morquio: relato de caso e revis\u00e3o da literatura","volume":"69","author":"Chaves","year":"2003","journal-title":"Rev. Bras. Otorrinolaringol."},{"issue":"8","key":"10.1016\/j.abb.2023.109541_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0012194","article-title":"Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice","volume":"5","author":"Dvorak-Ewell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.abb.2023.109541_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.J","volume":"37","author":"Hendriksz","year":"2014","journal-title":"Inherit. Metab. Dis"},{"key":"10.1016\/j.abb.2023.109541_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","article-title":"Home treatment with elaprase and Naglazyme is safe in patient with mucopolysaccharidoses types II and VI, respectivetly","volume":"31","author":"Bagewadi","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.abb.2023.109541_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jpeds.2007.10.015","article-title":"M.Sahhar, J.E. Wraith, M.B. Delatycki. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families","volume":"152","author":"Coman","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.abb.2023.109541_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10545-006-0239-6","article-title":"Limitations of enzyme replacement therapy: current and future","volume":"29","author":"Wraith","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.abb.2023.109541_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-014-0108-z","article-title":"Elosulfase alfa: a review of its use in patients with mucopolysaccharidosis type IVA (morquio A syndrome)","author":"Lyseng-Williamson","year":"2014","journal-title":"BioDrugs.28"},{"key":"10.1016\/j.abb.2023.109541_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijdevneu.2007.08.008","article-title":"Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy","volume":"25","author":"Deon","year":"2007","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.abb.2023.109541_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10571-008-9313-y","article-title":"L-carnitine blood levels and oxidative stress in treated PhenylketonuricPatients","author":"Sitta","year":"2009","journal-title":"Cell. Mol. Neurobiol.29"},{"issue":"9","key":"10.1016\/j.abb.2023.109541_bib11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbadis.2016.05.021","article-title":"Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation","volume":"1862","author":"Jacques","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.abb.2023.109541_bib12","first-page":"46","article-title":"D.P.Marchetti, C.E. Diaz Jacques. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: increased keratan urinary levels","volume":"25","author":"Donida","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.abb.2023.109541_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cca.2007.09.008","article-title":"Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy","volume":"387","author":"Pereira","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.abb.2023.109541_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cca.2005.07.022","article-title":"Blood oxidative stress markers in Gaucher disease patients","volume":"364","author":"Roversi","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.abb.2023.109541_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2011.02.016","article-title":"Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy","volume":"103","author":"Filippon","year":"2011","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.abb.2023.109541_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mrgentox.2011.02.005","article-title":"DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy","volume":"721","author":"Filippon","year":"2011","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen"},{"key":"10.1016\/j.abb.2023.109541_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tins.2011.02.005","article-title":"Toll-like receptor signaling in neural plasticity and disease","volume":"34","author":"Okun","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.abb.2023.109541_bib18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.redox.2014.02.006","article-title":"Hydrogen peroxide sensing, signaling and regulation of transcription factors","volume":"2","author":"Marinho","year":"2014","journal-title":"Redox Biol."},{"key":"10.1016\/j.abb.2023.109541_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10545-015-9861-5","article-title":"Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism","volume":"38","author":"Olsen","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.abb.2023.109541_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20111752","article-title":"Cell signalling by reactive lipid species: new concepts and molecular mechanisms","volume":"442","author":"Higdon","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.abb.2023.109541_bib21","first-page":"1","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol Genet Met Rep"},{"key":"10.1016\/j.abb.2023.109541_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5414\/CNP58344","article-title":"Correlative studies of urine fluorescence and free radical indicators","volume":"58","author":"Kirschbaum","year":"2002","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.abb.2023.109541_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0304-3940(01)01636-6","article-title":"Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease","volume":"302","author":"Aksenov","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.abb.2023.109541_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/cs0840407","article-title":"A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates","volume":"84","author":"Miller","year":"1993","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.abb.2023.109541_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s004310050685","article-title":"Selective screening of 10.000 high risk Brazilian patients for the detection of inborn errors of metabolism","volume":"156","author":"Coelho","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.abb.2023.109541_bib26","series-title":"Errores innatos en el metabolismo del ni\u00f1o","first-page":"225","article-title":"Errores innatos Del metabolism lisosomal","author":"Mabe","year":"2003"},{"key":"10.1016\/j.abb.2023.109541_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.abb.2023.109541_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International morquio A registry: clinical manifestation and natural course of morquio A disease","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.abb.2023.109541_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1750-1172-6-84","article-title":"Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers","volume":"6","author":"Martell","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.abb.2023.109541_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (morquio A disease): clinical review and current treatment: a special review","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.abb.2023.109541_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cuor.2005.12.003","article-title":"Morquio syndrome","volume":"20","author":"Lankaster","year":"2006","journal-title":"Curr. Orthop."},{"issue":"4","key":"10.1016\/j.abb.2023.109541_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: diagnosis, treatment, and management","volume":"21","author":"Sawamoto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2023.109541_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/B:BOLI.0000037353.13085.e2","article-title":"The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies","volume":"27","author":"Wajner","year":"2004","journal-title":"J InherMetab Dis"},{"key":"10.1016\/j.abb.2023.109541_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijdevneu.2007.08.008","article-title":"Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patient with x-linked adrenoleucodystrophy","author":"Deon","year":"2007","journal-title":"Int J Dev Neurosci.25(7)"},{"key":"10.1016\/j.abb.2023.109541_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijdevneu.2007.05.004","article-title":"Erythrocyte glutathione peroxidase activity and plasma selenium concentration are reduced in maple syrup urine disease patients during treatment","author":"Barschak","year":"2007","journal-title":"Int J Dev Neurosci.25(5)"},{"key":"10.1016\/j.abb.2023.109541_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijdevneu.2010.01.002","article-title":"Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of L-carnitine supplementation","volume":"28","author":"Ribas","year":"2010","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.abb.2023.109541_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.gene.2014.07.051","article-title":"Prevention of DNA damage by l-carnitine induced by metabolites accumulated in maple syrup urine disease in human peripheral leukocytes in vitro","volume":"548","author":"Mescka","year":"2014","journal-title":"Gene"},{"issue":"1\u20132","key":"10.1016\/j.abb.2023.109541_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-014-2322-x","article-title":"Increased oxidative stress in patients with 3-hydroxy-3-methylglutaric aciduria","volume":"402","author":"dos Santos","year":"2015","journal-title":"Mol. Cell. Biochem."},{"issue":"668","key":"10.1016\/j.abb.2023.109541_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.abb.2019.04.008","article-title":"Preventionby L-carnitineof DNA damageinducedby 3-hydroxy-3-methylglutaric and 3-methylglutaric acidsand experimental evidenceoflipidand DNA damage in patientswith 3-hydroxy-3-methylglutaric aciduria","volume":"15","author":"Delgado","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.abb.2023.109541_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14202\/vetworld.2018.627-635","article-title":"The crucial roles of inflammatory mediators in inflammation: a review","volume":"11","author":"Abdulkhaleq","year":"2018","journal-title":"Vet. World"},{"issue":"4","key":"10.1016\/j.abb.2023.109541_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.abb.2023.109541_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","article-title":"Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models","volume":"57","author":"Simonaro","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.abb.2023.109541_bib43","series-title":"Chapter 6, Inflammation and its Role in the Lysosomal Storage Disorders, Mucopolysaccharidoses Update","first-page":"75","volume":"vol. 1","author":"Simonaro","year":"2018"},{"key":"10.1016\/j.abb.2023.109541_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry","volume":"92","author":"Nagase","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.abb.2023.109541_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"E.H. Schuchman Involvement of the Toll-like receptor 4 pathway and use of TNF- antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.abb.2023.109541_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00011-018-1151-x","article-title":"A review on heme oxygenase-1 induction: is it a necessary evil","volume":"67","author":"Waza","year":"2018","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.abb.2023.109541_bib47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0002-9440(10)63365-2","article-title":"Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse","volume":"165","author":"Kapturczak","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.abb.2023.109541_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","article-title":"Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution","volume":"16","author":"Taguchi","year":"2011","journal-title":"Gene Cell."},{"issue":"5","key":"10.1016\/j.abb.2023.109541_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/icb\/icq034","article-title":"Nrf2, a guardian of healthspan and gatekeeper of species longevity","volume":"50","author":"Lewis","year":"2010","journal-title":"Integr. Comp. Biol."},{"issue":"4","key":"10.1016\/j.abb.2023.109541_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.abb.2023.109541_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-398339-8.00002-1","article-title":"The Keap1-Nrf2 cell defense pathway \u2013 a promising therapeutic target","volume":"63","author":"Copple","year":"2012","journal-title":"Adv. Pharmacol."},{"issue":"4","key":"10.1016\/j.abb.2023.109541_bib52","first-page":"341","article-title":"Nuclear facto kappa B: a new perspective for the study of anti-inflammatory drugs","volume":"12","author":"Blanco","year":"2003","journal-title":"Rev. Cienc. Med. (Lourenco Marques)"}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986123000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986123000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:22:55Z","timestamp":1757744575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986123000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":52,"alternative-id":["S0003986123000401"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2023.109541","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory process and oxidative\/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2023.109541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109541"}}